Skip to content
5 min read Therapeutic Thursday Oncology

Therapeutic Thursday: Launch Day Strength

Analysts see mega-blockbuster potential in Revolution’s Rasonque, but its CEO is tempering expectations. Sometimes the smartest move after a record launch is to ask everyone to hold the applause.

A blue wooden lifeguard hut with pink trim and railings and a large pink “VI” painted on its side, with palm tree silhouettes inside the letters.
Now that's how you launch. Photo by Ben Koorengevel on Unsplash

Welcome to Leonida!

For the uninitiated, Leonida is Rockstar’s take on the US state of Florida in its long-awaited open-world crime simulator Grand Theft Auto VI.

Over $1bn in estimated development costs, a plus 200GB pre-load and a 13-year wait all seem to be worth it as the game launched with rave reviews on Nov. 19. The run-up to the launch was special. The BBC had a countdown clock for the game’s UK launch.

Speaking of launches that lived up to the hype, remember Rasonque’s debut quarter numbers that came out earlier this month?  

Launch Momentum

Rasonque (daraxonrasib), a selective RAS(ON) inhibitor from Revolution Medicines, won FDA approval on Aug. 26 for second-line or later treatment of metastatic pancreatic adenocarcinoma (PDAC). In the roughly five weeks to Sept. 30, it booked $197.6m.

“Now that’s how you launch a drug,” Evercore ISI analyst Cory Kasimov said at the time. And Scrip did its own due diligence. The analysis of Evaluate data for 27 oncology drugs that eventually became blockbusters showed that the typical oncology launch starts small. But this was not a typical launch. It was the best launch-quarter sales for an oncology drug ever. The next best was more than $100m behind.

Let’s not go into too many spoilers for that exclusive take on Rasonque’s launch. You can read that one here.

During a post-game press conference after the Los Angeles Lakers took a 2–0 series lead over the Orlando Magic in the 2009 NBA Finals, basketball legend Kobe Bryant famously said, “What’s there to be happy about? Job’s not finished.” Revolution Medicines CEO Mark Goldsmith had that same air about him as he spoke at the Jefferies London Healthcare Conference, trying to temper expectations for Rasonque and its potential mega-blockbuster status.

Pressed on the $197.6m number, which reflects just five weeks of sales after the Aug. 26 approval, Goldsmith said the period was too variable to show a recognizable pattern. The reason is that three overlapping groups of patients have been treated so far.